Burnouf C, Auclair E, Avenel N, Bertin B, Bigot C, Calvet A, Chan K, Durand C, Fasquelle V, Féru F, Gilbertsen R, Jacobelli H, Kebsi A, Lallier E, Maignel J, Martin B, Milano S, Ouagued M, Pascal Y, Pruniaux M P, Puaud J, Rocher M N, Terrasse C, Wrigglesworth R, Doherty A M
Pfizer Global Research & Development, Fresnes Laboratories, 3 à 9 rue de la Loge, 94265 Fresnes, France.
J Med Chem. 2000 Dec 14;43(25):4850-67. doi: 10.1021/jm000315p.
The synthesis, structure-activity relationships, and biological properties of a novel series of potent and selective phosphodiesterase type 4 (PDE4) inhibitors are described. These new aminodiazepinoindoles displayed in vitro PDE4 activity with submicromolar IC(50) values and PDE4 selectivity vs PDE1, -3, and -5. Specifically, one compound (CI-1044, 10e) provided efficient in vitro inhibition of TNFalpha release from hPBMC and hWB with IC(50) values of 0.34 and 0.84 microM, respectively. This compound was found to exhibit potent in vivo activity in antigen-induced eosinophil recruitment in Brown-Norway rats (ED(50) = 3.2 mg/kg po) and in production of TNFalpha in Wistar rats (ED(50) = 2.8 mg/kg po). No emetic side effects at therapeutic doses were observed in ferrets.
描述了一系列新型强效和选择性4型磷酸二酯酶(PDE4)抑制剂的合成、构效关系及生物学特性。这些新型氨基二氮杂苯并吲哚在体外表现出PDE4活性,其半数抑制浓度(IC50)值为亚微摩尔级别,且对PDE4的选择性高于PDE1、-3和-5。具体而言,一种化合物(CI-1044,10e)能有效在体外抑制人外周血单核细胞(hPBMC)和人全血(hWB)释放肿瘤坏死因子α(TNFα),其IC50值分别为0.34和0.84微摩尔。该化合物在布朗-挪威大鼠抗原诱导的嗜酸性粒细胞募集实验(口服半数有效剂量[ED50]=3.2毫克/千克)以及在Wistar大鼠TNFα产生实验(口服ED50=2.8毫克/千克)中表现出强效体内活性。在雪貂中未观察到治疗剂量下的催吐副作用。